The relationship of serum soluble fas ligand (sFASL) level with the extent of coronary artery disease

International Journal of Angiology

Volumn 21, Issue 1, 2012, Pages 29-34

  Sahinarslan, Asife ^a   Boyaci, Bulent ^a   Kocaman, Sinan Altan ^a   Topal, Salih ^a   Ercin, Ugur ^a   Okyay, Kaan ^a   Bukan, Neslihan ^a   Yalçin, Ridvan ^a   Cengel, Atiye ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Atherosclerosis; Ischemic heart disease; Soluble fas ligand

Indexed keywords

FAS LIGAND;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

EID: 84859197362     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0032-1306418     Document Type: Article

References (27)

1. Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998;97(23):2307-2315 (Pubitemid 28280384)
2. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001;88(10):998-1003 (Pubitemid 34137111)
3. Nagata S. Apoptosis bydeath factor. Cell 1997;88(3):355-365
4. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133(2):335-343 (Pubitemid 26132532)
5. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998;4(4):415-420 (Pubitemid 28212756)
6. Nagata S, Golstein P. The Fas death factor. Science 1995;267(5203):1449- 1456
7. Jeremias I, Kupatt C,Martin-Villalba A, et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation 2000;102(8):915-920
8. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182(6):1777-1783
9. Okura T, Watanabe S, Jiang Y, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002;20(5):895-898 (Pubitemid 34913670)
10. Shimizu M, Fukuo K, Nagata S, et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002;39(4):585-590 (Pubitemid 34158152)
11. Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernan FJ. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000;86(2):205-207 (Pubitemid 30410728)
12. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998;4(4):415-420 (Pubitemid 28212756)
13. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62(5):337-342
14. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 2005;35(9):537-545 (Pubitemid 41243296)
15. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated withdownregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187(8):1205- 1213 (Pubitemid 28189110)
16. Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004;43:1188-1194 (Pubitemid 38452595)
17. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al; ACTFAST investigators. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007;27(1):168-174 (Pubitemid 46360395)
18. Blanco-Colio LM, Martín-Ventura JL, Tuñón J, García-Camarero T, Berrazueta JR, Egido J. Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function? Atherosclerosis 2008;201:407-412
19. Esaki T, Hayashi T, Muto E, et al. Expression of inducible nitric oxide synthase and Fas/Fas ligand correlates with the incidence of apoptotic cell death in atheromatous plaques of human coronary arteries. Nitric Oxide 2000;4(6):561-571 (Pubitemid 32053267)
20. Hansson GK, Geng YJ, Holm J, Hårdhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180(2):733-738 (Pubitemid 24224154)
21. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001;103(25):3099-3104 (Pubitemid 32587858)
22. Setsuta K, Seino Y, Ogawa T, Ohtsuka T, Seimiya K, Takano T. Ongoing myocardial damage inchronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 2004;68(8):747-750 (Pubitemid 39044955)
23. Masse M, Hébert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is amarker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant 2002;17(3):485-491 (Pubitemid 34211148)
24. Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is amarker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 2001;38(6):1271-1276 (Pubitemid 34193113)
25. van der Meer IM, Oei HH, Hofman A, Pols HAP, de Jong FH, Witteman JCM. Soluble Fas, amediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calci.cation Study. Atherosclerosis 2006;189(2):464-469 (Pubitemid 44634493)
26. Van de Werf F, Bax J, Betriu A, et al; ESC Committee for Practice Guidelines (CPG)Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945
27. Bassand JP, Hamm CW, Ardissino D, et al Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28(13):1598-1660